Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CLL gets to MRD with combo therapy

Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Key clinical point: Ibrutinib plus venetoclax produced a high rate of undetectable minimal residual disease.

Major finding: Of 14 patients, 12 (86%) who completed 12 cycles of treatment had undetectable bone marrow MRD.

Study details: Early results of the phase 2 CAPTIVATE trial including 164 patients younger than 70 years of age with previously untreated CLL.

Disclosures: The study was sponsored by Pharmacyclics, an Abbvie company. Dr. Wierda reported consulting and research funding from Pharmacyclics, AbbVie, and several other companies.

Source: Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Read the article.

Citation:

Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

This Week's Must Reads

Oncologists file suit challenging Part B payment reductions, May 30 letter to HHS Secretary Alex Azar alerting him to the legal action, which was filed on May 31.

One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Must Reads in CLL

CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11

Updated CLL guidelines, Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

Prognostic Testing Patterns, CLL Outcomes Assessed, Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 5; Mato, et al

Liver Dysfunction in Chronic Lymphocytic Leukemia, Am J Hematol; ePub 2017 Oct 19; Hampel, et al